Previous 10 | Next 10 |
BioLife Solutions ( NASDAQ: BLFS ) reported preliminary and unaudited Q4 revenue of $44.M, an increase of 19% Y/Y, vs consensus of $43.42M . COVID related revenue accounted for ~5% of total revenue. Q4 Cell processing platform revenue was $20.3M, up $5.5M, or 37% Y/Y. All grow...
BioLife Solutions Announces 2022 Fourth Quarter and Full Year Preliminary Unaudited Revenue and Introduces 2023 Revenue Guidance PR Newswire Record quarterly revenue of $44.4 million up 19% over Q4 2021 with Cell Processing Platform revenue growth of 37% Record ful...
Summary BioLife Solutions, Inc. guidance narrowed for full-year estimates, whilst there were several observable challenges exhibited in Q3 numbers. It could be a while before the company returns back to profitability, hence, the investment and valuation metrics don't stack up at present...
BioLife Solutions to Announce Preliminary 2022 Revenue and Introduce 2023 Revenue Guidance on January 9, 2023 PR Newswire Announcement Precedes Meetings to be Held During the J.P. Morgan Health Care Conference; Updated Investor Presentation Demonstrates Continued Execution to ...
BioLife Solutions Expands Intellectual Property Estate PR Newswire 7 New Granted Patents; 43 Submitted Patent Applications Global Portfolio Now Totals 148 Issued and 114 Pending Patents BOTHELL, Wash. , Nov. 21, 2022 /PRNewswire/ -- Bi...
BioLife Solutions Named in BioSpace Best Places to Work in Biopharma 2023 Report PR Newswire Only 60 Companies Selected – Based on 2,000 Respondents BOTHELL, Wash. , Nov. 17, 2022 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BL...
Summary Despite macroeconomic concerns, Cryoport is still generating a 7% revenue growth for the quarter. The new Houston facility that is in collaboration with Takeda would start generating sales as soon as next year. Recent acquisitions this year would position Cryoport as a...
Summary In today's issue of the 1-Minute Market Report, I examine the market bounce since the October low, and highlight the areas of the market that are leading the way higher. On Thursday, for every stock that was down, there were 26 that were up. For the first time since August...
BioLife Solutions, Inc. (BLFS) Q3 2022 Earnings Conference Call November 09, 2022 04:30 PM ET Company Participants Troy Wichterman - Chief Financial Officer Mike Rice - Chairman & Chief Executive Officer Rod de Greef - President & Chief Operating Officer ...
BioLife Solutions press release ( NASDAQ: BLFS ): Q3 GAAP EPS of -$0.23 misses by $0.06 . Adjusted net loss (non-GAAP) for the third quarter of 2022 was $6.6 million compared with adjusted net loss of $8.3 million for the third quarter of 2021. Revenue of $40.7M (+...
News, Short Squeeze, Breakout and More Instantly...
BioLife Solutions Inc. Company Name:
BLFS Stock Symbol:
NASDAQ Market:
BioLife Solutions Inc. Website:
BioLife Solutions to Report Second Quarter 2024 Financial Results and Business Update on August 8, 2024 PR Newswire BOTHELL, Wash. , July 25, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction...
BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouv...
BioLife Solutions Reports First Quarter 2024 Financial Results PR Newswire Cell Processing revenue increased 10% sequentially to $16.2 million GAAP gross margin of 38% and net loss of $10.2 million Non-GAAP adjusted gross margin expands ...